Thursday, Propanc Biopharma, Inc. (PPCB) announced that its board has approved a share repurchase program, authorizing the company to repurchase up to $5.0 million of its common stock.
The company expects the program to allow the shareholders to continue to increase their ownership in its underlying assets, improve per share economics over time, and signal management's confidence in the long-term value of the business.
Moreover, CEO James Nathanielsz stated that the decision reflects the company's commitment to disciplined, flexible capital allocation.
In the pre-market hours, PPCB is trading at $2.87, up 114.23 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.